Gamma-delta T lymphocytes and 25-hydroxy Vitamin D levels as key factors in autoimmunity and inflammation: The case of zoledronic acid-induced acute phase reaction

Lupus

Volumn 24, Issue 4-5, 2015, Pages 442-447

  De Santis, M ^a,b   Cavaciocchi, F ^a,b   Ceribelli, A ^a,b   Crotti, C ^a   Generali, E ^a   Fabbriciani, G ^a   Selmi, C ^a,c   Massarotti, M ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse event; Bisphosphonate; Bone loss; Osteoporosis; Zoledronate

Indexed keywords

CALCIFEDIOL; ZOLEDRONIC ACID; 25-HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; VITAMIN D;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; AUTOIMMUNITY; BLOOD SAMPLING; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLASSIFICATION; IMMUNOLOGY; MIDDLE AGED; T LYMPHOCYTE SUBPOPULATION; VERY ELDERLY;

ACUTE-PHASE REACTION; AGED; AGED, 80 AND OVER; AUTOIMMUNITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TH1 CELLS; VITAMIN D;

EID: 84925615613     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314559633     Document Type: Article

References (24)

1. Caccamo N, Meraviglia S, Ferlazzo V, et al. (2005) Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vã9Vä2 naïve, memory and effector T cell subsets. Eur J Immunol 2005; 35: 1764-1772.
2. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonates administration. Calcif Tissue Int 1987; 41: 326-331.
3. Ribot JC, Silva-Santos B. Differentiation and activation of γδ T lymphocytes: Focus on CD27 and CD28 costimulatory receptors. Adv Exp Med Biol 2013; 785: 95-105.
4. Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta Tlymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102: 2310-2311.
5. Rossini M, Adami S, Viapiana O, et al. Long-term effects of aminobisphosphonates on circulating γδ T cells. Calcif Tissue Int 2012; 91: 395-399.
6. Sutton CE, Mielke LA, Mills KHG. IL-17-producing γδ T cells and innate lymphoid cells. Eur J Immunol 2012; 42: 2221-2231.
7. Bertoldo F, Pancheri S, Zenati S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 2010; 25: 447-548.
8. Chen L, Cencioni MT, Angelini DF, et al. Transcriptional profiling of gamma delta T cells identifies a role for vitamin D in the immunoregulation of the V gamma 9V delta 2 response to phosphatecontaining ligands. J Immunol 2005; 174: 6144-6152.
9. Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol 2013; 29: 1005-1410.
10. Dimitroulas T, Nikas SN, Trontzas P, Katas GD. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 2013; 12: 958-966.
11. Caetano-Lopes J, Rodrigues J, Lopes A, et al. Rheumatoid arthritis bone fragility is associated with upregulation of il17 and dkk1 gene expression. Clin Rev Allergy Immuno 2014; 47: 38-45.
12. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune disease. Clin Rev Allergy Immuno 2013; 45: 256-266.
13. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: A comprehensive review. Clin Rev Allergy Immuno 2013; 45: 217-226.
14. Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: Lessons learned from genomewide analysis. Front Physiol 2014; 21: 151.
15. Welton JL, Morgan MP, Marti S, et al. Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: Insights from a phase IV safety trial. J Bone Miner Res 2013; 28: 464-471.
16. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974-4980.
17. Sireci G, Espinosa E, Di Sano C, Dieli F, Fournié JJ, Salerno A. Differential activation of human gammadelta cells by nonpeptide phosphoantigens. Eur J Immunol 2001; 31: 1628-1635.
18. Ribot JC, Chaves-Ferreira M, d'Orey F, et al. Cutting edge: Adaptive versus innate receptor signals selectively control the pool sizes of murine INF-α - or IL-17-producing γδ T cells upon infection. J Immunol 2010; 185: 6421-6425.
19. Caccamo N, Todaro M, Sireci G, Meraviglia S, Stassi G, Dieli F. Mechanisms underlying lineage commitment and plasticity of human γδ T cells. Cell Mol Immunol 2013; 10: 30-34.
20. Chien YH, Zeng X, Prinz I. The natural and the inducible: Interleukin (IL)-17-producing γδ T cells. Trends Immunol 2013; 34: 151-154.
21. Haas JD, Ravens S, Düber S, et al. Development of interleukin-17- producing γδ T cells is restricted to a functional embryonic wave. Immunity 2012; 37: 48-59.
22. Zeng X, Wei YL, Huang J, et al. γδ T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin- 17 response. Immunity 2012; 37: 524-534.
23. Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol 2010; 184: 7268-7280.
24. Caccamo N, La Mendola C, Orlando V, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 2011; 118: 129-138.